Silencing LINC00460 inhibits proliferation and migration of human lung adenocarcinoma cell lines via EZH2

doi:10.16352/j.issn.1001-6325.2025.10.1298

Abstract

Abstract: Objective To investigate the expression of long non-coding RNA LINC00460 in lung adenocarcinoma (LUAD) and its effects on cell proliferation and migration. Methods Quantitative real-time polymerase chain reaction (RT-qPCR) was used to detect the expression of LINC00460 in LUAD cell lines (PC-9,A549,NCI-H1975 and H1299) and normal lung cell line (MRC-5). LINC00460 was silenced in A549 and H1299 cells using small interfering RNA (siRNA), followed by cell proliferation assessment with CCK-8 assay and evaluation of cell migration capacity through the Transwell assay. Fluorescence in situ hybridization (FISH) and RNA immunoprecipitation (RIP) assays were performed to determine the subcellular localization of LINC00460 and its interaction with EZH2. Western blot was applied to examine EZH2 and H3K27me3 expression in cells. Results LINC00460 was highly expressed in LUAD cells, and the expression level was significantly decreased after silencing (P＜0.001). Silencing LINC00460 markedly inhibited the proliferation and migration of A549 and H1299 cells (P＜0.001). LINC00460 was primarily localized in the nucleus. RIP assays confirmed a significant interaction between LINC00460 and EZH2 (P＜0.001). Furthermore, the silencing of LINC00460 resulted in a significant reduction in the expression of EZH2 and its downstream target H3K27me3 (P＜0.001). Conclusions LINC00460 is highly expressed in LUAD cells. Silencing LINC00460 inhibits cell proliferation and migration through EZH2. This mechanism provides a basis for LINC00460 as a potential therapeutic target in lung adenocarcinoma.

Key words: lung adenocarcinoma, LINC00460, EZH2, H3K27me3

CLC Number:

R734.2

ZENG Cimei, HUANG Denggao, WANG Lei, LIANG Haimei, MA Ximiao. Silencing LINC00460 inhibits proliferation and migration of human lung adenocarcinoma cell lines via EZH2[J]. Basic & Clinical Medicine, 2025, 45(10): 1298-1305.

References

[1] Wei X, Li X, Hu S, et al. Regulation of ferroptosis in lung adenocarcinoma[J]. Int J Mol Sci, 2023, 24: 14614. doi: 10.3390/ijms241914614.
[2] 王布, 袁胜芳, 张长洪, 等. eEF2K沉默联合丹参酮ⅡA磺酸钠协同抑制人肺腺癌细胞系A549增殖[J]. 基础医学与临床, 2022, 42: 106-113. doi: 10.16352/j.issn.1001-6325.2022.01.017.
[3] Ren Q, Zhang P, Lin H, et al. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts[J]. Front Immunol, 2023, 14: 1201573. doi: 10.3389/fimmu.2023.1201573.
[4] Nakano Y, Isobe K, Kobayashi H, et al. Clinical importance of long non-coding RNA LINC00460 expression in EGFR-mutant lung adenocarcinoma[J]. Int J Oncol, 2020, 56: 243-257. doi: 10.3892/ijo.2019.4919.
[5] 曾慈梅, 欧宗兴, 黄邓高, 等. 非小细胞肺癌中长链非编码RNA LINC00460表达及其临床意义[J]. 中国热带医学, 2019, 19: 692-695. doi: 10.13604/j.cnki.46-1064/r.2019.07.22.
[6] Xie H, Xu W, Liang J, et al. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma[J]. Bioorg Chem, 2023, 140: 106762. doi: 10.1016/j.bioorg.2023.106762.
[7] Xu H, Ye W, Shi B. LncRNA MALAT1 regulates USP22 expression through EZH2-mediated H3K27me3 modifica-tion to accentuate sepsis-induced myocardial dysfunction[J]. Cardiovasc Toxicol, 2022, 22: 813-830. doi: 10.1007/s12012-022-09758-2.
[8] Yang F, Dong Z, Shen Y, et al. Cribriform growth pattern in lung adenocarcinoma: more aggressive and poorer prognosis than acinar growth pattern[J]. Lung Cancer, 2020, 147: 187-192. doi: 10.1016/j.lungcan.2020.07.021.
[9] Chen X, Song J, Wang X, et al. LncRNA LINC00460: function and mechanism in human cancer[J]. Thorac Cancer, 2022, 13: 3-14. doi: 10.1111/1759-7714.14238.
[10] Li W, Feng SS, Wu H, et al. Comprehensive analysis of CDK1-associated ceRNA network revealing the key pathways LINC00460/LINC00525-Hsa-Mir-338-FAM111/ZWINT as prognostic biomarkers in lung adenocarcinoma combined with experiments[J]. Cells, 2022, 11: 1220. doi: 10.3390/cells11071220.
[11] Li J, Huang S, Zhang Y, et al. LINC00460 enhances bladder carcinoma cell proliferation and migration by modulating miR-612/FOXK1 axis[J]. Pharmacology, 2021, 106: 79-90. doi: 10.1159/000509255.
[12] Li XJ, Zhou F, Li YJ, et al. LncRNA H19-EZH2 interaction promotes liver fibrosis via reprogramming H3K27me3 profiles[J]. Acta Pharmacol Sin, 2023, 44: 2479-2491. doi: 10.1038/s41401-023-01145-z.
[13] Onishi T, Takashima T, Kurashige M, et al. Mutually exclusive expression of EZH2 and H3K27me3 in non-small cell lung carcinoma[J]. Pathol Res Pract, 2022, 238: 154071. doi: 10.1016/j.prp.2022.154071.
[14] W-M Fan T, Islam JMM, Higashi RM, et al. Metabolic reprogramming driven by EZH2 inhibition depends on cell-matrix interactions[J]. J Biol Chem, 2024, 300: 105485. doi: 10.1016/j.jbc.2023.105485.
[15] Wang SQ, Liu J, Qin J, et al. CAMK2A supported tumor initiating cells of lung adenocarcinoma by upregulating SOX2 through EZH2 phosphorylation[J]. Cell Death Dis, 2020, 11: 410. doi: 10.1038/s41419-020-2553-6.